Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord
Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...
Vertex Pharmaceuticals (VRTX) Receives a Buy from Piper Sandler
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...